The following is a general summary of certain material U.S. federal income tax consequences relating to the purchase, ownership and disposition of our ordinary shares by U.S. Holders (as defined below). This summary is based on the Code, the regulations of the U.S. Department of the Treasury issued pursuant to the Code, or the Treasury Regulations, the income tax treaty between the United States and Israel, or the U.S.-Israel Tax Treaty, and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect, or to different interpretation. No ruling has been sought from the IRS with respect to any U.S. federal income tax consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position. This summary is no substitute for consultation by prospective investors with their own tax advisors and does not constitute tax advice. This summary applies only to U.S. Holders that hold our ordinary shares as capital assets for U.S. federal income tax purposes (generally, property held for investment) and does not address all of the tax considerations that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment under U.S. federal income tax law (including, without limitation, banks, insurance companies, tax-exempt entities, retirement plans, regulated investment companies, partnerships, dealers in securities, brokers, real estate investment trusts, certain former citizens or residents of the United States, persons who acquire our ordinary shares as part of a straddle, hedge, conversion transaction or other integrated investment, persons who acquire our ordinary shares through the exercise or cancellation of employee stock options or otherwise as compensation for their services, persons that have a “functional currency” other than the U.S. dollar, persons that own (or are deemed to own, indirectly, or by attribution) 10% or more of our shares (by vote or value), or persons that mark their securities to market for U.S. federal income tax purposes). This summary does not address any U.S. state or local or non-U.S. tax considerations, any U.S. federal estate, gift or alternative minimum tax considerations, or any U.S. federal tax consequences other than U.S. federal income tax consequences.

Surface plasma modification is an excellent approach to modify the chemical structure26 and produce the targeted nitrogen functionality27,28,29. It has been demonstrated that a nitrogen plasma-modified surface can serve as a powerful artificial microenvironment to regulate osteogenic differentiation of osteoblasts30,31,32. However, the inherently complicated chemical structure of many biopolymers containing C-H, C-O, C = O, C-N, and N-H bonds makes it difficult to controllably construct the specific nitrogen functionality to attain the desirable biological outcome33,34. Therefore, previous results concerning the effects of plasma-generated nitrogen functionalities such as primary, secondary, and tertiary amines on bone cells are ambiguous and sometimes contradictory30,31,32,33. In this study, the inherent chemical bonds are dissociated and O and H are sputtered off by argon ion bombardment to convert the polymeric surface into a simple carbonaceous structure28,35. The preparation procedures are illustrated by Step 1 in Fig. 1a. Raman scattering reveals that the D and G bands at 1330 cm−1 and 1580 cm−1 are typical of pyrolytic carbon (Fig. 1b, PAr). The broadened D bands of PAr and PArN indicate that there are many structural defects and lack of spatial uniformity and disappearance of the 2D band also suggests a lack of spatial uniformity. The G band is often detected from sp2 systems originating from in-plane vibrations and suggests C = C bond formation in PAr. ATR-FTIR and XPS also confirm that a pyrolytic carbon structure is produced on the PE substrate after Ar ion bombardment (Figs. 1c and 1d, PAr). By considering the decreased peaks corresponding to vibrations of -CH2 at 1061 nm, 1130 nm, 1293 nm, and 1439 nm in the Raman spectra (Fig. 1b, PAr), larger amounts of C-, C4H- and C6H-, and reduced amounts of C3H5- and C7H7- ions in the TOF-SIMS spectrum (Fig. 1e, PAr), it can be inferred that during argon ion bombardment, dissociation of the chemical bonds occurs and hydrogen is sputtered off from the PE molecular chain leading to the formation of pyrolytic carbon.

        Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.

        (2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

        The net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our

Seo, B. M. et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet. 364, 149–155 (2004).

Capstone Therapeutics (NasdaqGM: CAPS ) Capstone Therapeutics (trade name of OrthoLogic Corp.) is a biotechnology company committed to developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. The Company is focused on development and commercialization of two product platforms: AZX100 and Chrysalin® (rusalatide acetate or TP508). AZX100 is a novel synthetic 24-amino acid peptide, one of a new class of compounds in the field of smooth muscle relaxation and fibrosis. Based on its demonstrated effects in pre-clinical models and safety in clinical trials, AZX100 is currently being evaluated for commercially significant medical applications such as the prevention or reduction of hypertrophic and keloid scarring, treatment of pulmonary disease and intimal hyperplasia. Capstone has an exclusive worldwide license to AZX100. Chrysalin, the Company’s novel synthetic 23-amino acid peptide, has been proven in multiple pre-clinical and clinical models to stimulate cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. It is currently being evaluated in disorders that involve vascular endothelial dysfunction, such as acute myocardial infarction and chronic myocardial ischemia. The Company owns exclusive worldwide rights to Chrysalin.

Grosso, A. F. et al. Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome. Diabetology & metabolic syndrome 6, 47, doi: 10.1186/1758-5996-6-47 (2014).

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

So rather than kissing my wife under the mistletoe this year, I’m going to reach up and eat the stuff, thus confirming what she’s always suspected about me.

激素治疗癌症最主要的优势是不会引起类似细胞毒物质一样的骨髓抑制。精确的抗癌机制不是完全清楚。最常用于治疗乳腺癌和前列腺癌，以及子宫内膜癌和子宫癌。此类药物包括：

Bachem and Axon Neuroscience SE today announced that the two companies have entered into a collaboration under which Bachem manufactures Axon’s investigational API and supplies it as a finished dosage form under Bachem’s Clinalfa brand.